Advice
following a full submission:
aflibercept intravitreal (Eylea®) is accepted for use within NHS Scotland.
Indication under review: For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion.
Two randomised double-masked studies demonstrated that aflibercept improved best corrected visual acuity significantly more than sham injections in treatment-naïve adults with macular oedema secondary to central retinal vein occlusion.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of aflibercept. This SMC advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice162KB (PDF)
Medicine details
- Medicine name:
- aflibercept intravitreal (Eylea®)
- SMC ID:
- 954/14
- Indication:
- For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion.
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Eye
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 April 2014